Unknown PHASE2 INTERVENTIONAL 2-arm NCT05108025

DMT310-005 Topical in the Treatment of Acne Rosacea

A Study Of The Tolerability, Safety, And Efficacy Of DMT310 For The Treatment Of Acne Rosacea

Sponsor: Dermata Therapeutics

Interventions Placebo Topical Powder Topical Powder

Updated 7 times since 2021 Last updated: Dec 7, 2022 Started: Nov 15, 2021 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acne Rosacea and is currently ongoing. Dermata Therapeutics leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE2

Status: Active Not Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2022 — Jan 2023 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Jan 2022 — Sep 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dermata Therapeutics

Data source: Dermata Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States